PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-50.49%
Negative EBIT growth while Healthcare median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-15.26%
Negative operating income growth while Healthcare median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-50.43%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-43.14%
Negative EPS growth while Healthcare median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-43.14%
Negative diluted EPS growth while Healthcare median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
5.01%
Share change of 5.01% while Healthcare median is zero. Walter Schloss would see if the modest difference matters long-term.
5.01%
Diluted share change of 5.01% while Healthcare median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
-30.81%
Negative OCF growth while Healthcare median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-30.34%
Negative FCF growth while Healthcare median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-52488.47%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-16557.44%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-182.36%
Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-47013.60%
Negative 10Y net income/share CAGR vs. Healthcare median of 1.93%. Seth Klarman might see a fundamental problem if peers maintain growth.
-7873.57%
Negative 5Y CAGR while Healthcare median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-9.65%
Negative 3Y CAGR while Healthcare median is 0.25%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
20722.38%
Equity/share CAGR of 20722.38% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
5960.52%
5Y equity/share CAGR of 5960.52% while Healthcare median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
359.30%
3Y equity/share CAGR of 359.30% while Healthcare median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-9.39%
Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-49.71%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
10.16%
R&D growth of 10.16% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
23.98%
SG&A growth of 23.98% while Healthcare median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.